Tscan Therapeutics is trading 5.27% down now at $0.34, with the decline appearing mainly sector-driven. - No new company-specific announcement or filing was identified for September 24, 2026. - The latest major update remains the September 2 strategic reorganization, which paused some programs and prioritized solid-tumor development. - Biotech ETF XBI is down 2.04% amid higher Treasury yields, inflation concerns, and broader risk-off pressure.